Tandem Diabetes Care, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US8753722037
USD
20.71
1.09 (5.56%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Tandem Diabetes Care, Inc. stock-summary
stock-summary
Tandem Diabetes Care, Inc.
Pharmaceuticals & Biotechnology
Tandem Diabetes Care, Inc. is a medical device company engaged in the designing, developing and commercialization of products for people with insulin-dependent diabetes. The Company’s manufacturing, sales and support activities principally focus on its flagship pump platform, the t:slim X2 Insulin Delivery System (t:slim X2), and its product offerings. The t:slim X2 is based on its technology platform and is capable of remote feature updates and is designed to display continuous glucose monitoring (CGM) sensor information directly on the pump home screen. Its products also include Basal-IQ technology and Control-IQ technology. The Basal-IQ technology is a predictive low glucose suspend feature that is designed to temporarily suspend insulin delivery to help reduce the frequency and duration of hypoglycemic events. The Control-IQ technology is a hybrid-closed loop feature, designed to help increase a user's time in targeted glycemic range.
Company Coordinates stock-summary
Company Details
11075 Roselle St , SAN DIEGO CA : 92121-1204
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 87 Schemes (59.77%)

Foreign Institutions

Held by 152 Foreign Institutions (16.83%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Kim Blickenstaff
Chairman of the Board
Mr. John Sheridan
President, Chief Executive Officer, Director
Mr. Dick Allen
Lead Independent Director
Mr. Rajwant Sodhi
Director
Mr. Edward Cahill
Independent Director
Ms. Peyton Howell
Independent Director
Kathleen McGroddy-Goetz
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
241 Million
(Quarterly Results - Jun 2025)
Net Profit:
-52 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 845 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.10

stock-summary
Return on Equity

-82.74%

stock-summary
Price to Book

6.34